Share on StockTwits

Synageva BioPharma Corp (NASDAQ:GEVA) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 3,582,645 shares, an increase of 34.7% from the July 15th total of 2,659,950 shares, Stock Ratings Network.com reports. Based on an average daily trading volume, of 335,066 shares, the short-interest ratio is currently 10.7 days. Approximately 11.1% of the company’s shares are sold short.

A number of research firms have recently commented on GEVA. Analysts at Janney Montgomery Scott reiterated a “fair value” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They now have a $111.00 price target on the stock, up previously from $107.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They now have a $110.00 price target on the stock, down previously from $115.00. Finally, analysts at Citigroup Inc. initiated coverage on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They set a “neutral” rating and a $113.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Synageva BioPharma Corp has a consensus rating of “Buy” and an average target price of $109.11.

Synageva BioPharma Corp (NASDAQ:GEVA) opened at 69.16 on Thursday. Synageva BioPharma Corp has a 1-year low of $44.52 and a 1-year high of $119.42. The stock’s 50-day moving average is $78.05 and its 200-day moving average is $86.44. The company’s market cap is $2.294 billion.

Synageva BioPharma Corp (NASDAQ:GEVA) last posted its quarterly earnings results on Friday, August 1st. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($1.37) by $0.15. On average, analysts predict that Synageva BioPharma Corp will post $-6.16 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.